Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16879015 | 1.00 | PNMT (0.67) | PNMTADRA2A | |
| Hydrochloric Acid SCHEMBL18765647 | 0.98 | PNMT (0.65) | PNMTADRA2A | |
| Hydrochloric Acid SCHEMBL18765650 | 0.98 | PNMT (0.65) | PNMTADRA2A | |
| SCHEMBL11728313 | 0.93 | PNMT (0.58) | PNMTADRA2A | |
| SCHEMBL11728324 | 0.93 | PNMT (0.58) | PNMTADRA2A | |
| SCHEMBL11728320 | 0.93 | PNMT (0.58) | PNMTADRA2A | |
| SCHEMBL5682319 | 0.81 | PNMT (0.69) | PNMTADRA2A | |
| SCHEMBL3117075 | 0.81 | PNMT (0.48) | PNMTADRA2A | |
| SCHEMBL2490240 | 0.80 | PNMT (1.00) | PNMTADRA2A | |
| SCHEMBL19329058 | 0.80 | PNMT (0.61) | PNMTADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230019032-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-01-19 | — | — | US | disclosed |
| US-11001575-B1 | Benzolactam compounds as protein kinase inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-05-11 | — | — | US | disclosed |
| US-10457669-B2 | Benzolactam compounds as protein kinase inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-10-29 | — | — | US | disclosed |
| US-20190047990-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-02-14 | — | — | US | disclosed |
| WO-2017068412-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-04-27 | — | — | WO | disclosed |
| WO-2015103527-A1 | MODULATORS OF REV-ERB | THE SCRIPPS RESEARCH INSTITUTE (US) | 2015-07-09 | — | — | WO | disclosed |
| WO-2015103527-A1 | MODULATORS OF REV-ERB | THE SCRIPPS RESEARCH INSTITUTE (US) | 2015-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230019032-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | MAPK1, ALK, MAP3K1 | PNMT 1178/4885ADRA2A 2563/4885 |
| US-20190047990-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | MAPK1, ALK, MAP3K1 | PNMT 1178/4885ADRA2A 2563/4885 |
| US-11001575-B1 | Benzolactam compounds as protein kinase inhibitors | MAPK1, ALK, MAP3K1 | PNMT 1211/4885ADRA2A 2644/4885 |
| US-10457669-B2 | Benzolactam compounds as protein kinase inhibitors | MAPK1, ALK, MAP3K1 | PNMT 1178/4885ADRA2A 2563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.